A filing for a bispecific antibody, and more time after a therapy gets more responses.
Amivantamab filing for Janssen. On Friday, Janssen announced it had submitted a biologics license application (BLA) seeking FDA approval for amivantamab for the treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations and disease progression, for patients who are on chemotherapy or have concluded platinum-based chemotherapy. Animvantamab is a bispecific antibody that targets both EGFR, which are very common in NSCLC, as well as mesenchymal epithelial transition (MET) factor. Submission is based on results from the phase I CHRYSALIS trial, which were presented at the American Society of Clinical Oncology virtual program in May. Findings showed a 36% overall response rate, including a 41% response rate in patients who had previously received platinum-based chemotherapy. Data from the trial also support creation of an expanded access program, allowing some patients to be treated while FDA weighs approval of the BLA.
Balstilimab BLA filing to be completed in early 2021. On Thursday, Agenus announced an updated timeline for submitting feedback that FDA seeks to complete its BLA filing for balstilimab, an investigational immunotherapy to treat recurrent or metastatic cervical cancer. FDA requires feedback on all patients for a median of 12 months and responders for a minimum of 6 months. Additional follow-up is now required to present data on 2 patients who experienced duration stabilization and “converted to confirmed responses on long-term balstilimab therapy,” the company said in a statement.
Microplastics, Diet and More: What’s Causing Early-Onset Cancer?
March 18th 2025In a February 2025 Time magazine cover story, Jamie Ducharme reports on this atypical and disquieting trend. Ducharme cites a 79% increase in early-onset cancer diagnoses and a 28% increase in cancer-related deaths in this age group from 1990 to 2019.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
CIBMTR Ranks Cedars-Sinai Cancer Among Top Transplant Programs in the U.S.
February 9th 2025Cedars-Sinai was one of 12 among 172 adult transplant centers in the U.S. with a one-year patient post-transplant survival rate above the expected outcome. In 2024, the survival rate for Cedars-Sinai was 90% versus the expected rate of 68% to 83%.
Read More